University of Kashan Journal of Nanostructures 2251-7871 15 2 2025 04 01 CD19-Targeted Lipid Nanoparticles for Delivering Venetoclax and BCL2 siRNA in B-Cell Acute Lymphoblastic Leukemia 587 595 114856 10.22052/JNS.2025.02.019 EN Oblokulov Abdurashid Department of Infectious Diseases and Infectious Diseases of children, Bukhara State Medical Institute Named After Abu Ali ibn Sino, Bukhara, Uzbekistan Indiaminova Gulrukh Department of Obstetrics and Gynaecology, Samarkand State Medical University, Samarkand, Uzbekistan Urmanova Gulbaхor Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan Ganieva Nafisa Faculty and Hospital Therapy, Occupational Diseases, Tashkent Medical Academy, Uzbekistan Kutumova Gullola Tashkent State Technical University, Uzbekistan Jumaeva Malokhat Department of Nuclear Medicine and Medical Radiology, Bukhara State Medical Institute Named After Abu Ali ibn Sino, Bukhara, Uzbekistan Mavlyanova Shakhnoza Medical Center for Dermatovenerology and Cosmetology, Ministry of Health of the Republic of Uzbekistan Saidaliyev Sultangazi Department of General Surgery, Fergana Medical Institute of Public Health, Uzbekistan Ruzibayeva Yorkinoy Department of Epidemiology and Infectious Disease Treatment, Nursing, Fergana Medical Institute of Public Health, Uzbekistan Abdutolibov Muhriddin Andijan State University, Uzbekistan Matkarimov Inomjon Mamun University, Uzbekistan Rakhimova Oygul Department of Industrial Technology of Medicines, Tashkent Pharmaceutical Institute, Tashkent, Uzbekistan Dushamov Dilshod Department of Chemistry, Urgench State University, Urgench, Uzbekistan Journal Article 2025 01 24 B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive hematologic malignancy characterized by uncontrolled proliferation of immature B lymphocytes. Current therapeutic approaches, including chemotherapy and monoclonal antibodies, face challenges such as drug resistance and systemic toxicity. CD19-targeted lipid nanoparticles (LNPs) represent a promising strategy for precision medicine by enhancing drug delivery specificity and overcoming apoptotic resistance. Venetoclax, a potent BCL-2 inhibitor, and BCL2 siRNA, a gene-silencing agent, offer a synergistic approach to combat leukemic cell survival mechanisms. By co-delivering these therapeutic agents through LNPs, the targeted modulation of apoptotic pathways can improve treatment efficacy while minimizing off-target effects. This review explores the rationale, formulation, and clinical prospects of CD19-targeted lipid nanoparticles for co-delivery of Venetoclax and BCL2 siRNA in B-ALL therapy, highlighting their potential to revolutionize leukemia treatment.   https://jns.kashanu.ac.ir/article_114856_44dc7fe4ecd3820566c0f52cb35b7d87.pdf